Farther Finance Advisors LLC reduced its position in Danaher Co. (NYSE:DHR – Free Report) by 3.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,841 shares of the conglomerate’s stock after selling 209 shares during the period. Farther Finance Advisors LLC’s holdings in Danaher were worth $1,902,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. CarsonAllaria Wealth Management Ltd. acquired a new stake in Danaher during the 2nd quarter valued at approximately $25,000. nVerses Capital LLC acquired a new stake in shares of Danaher during the second quarter worth approximately $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Danaher in the second quarter worth $51,000. Financial Connections Group Inc. acquired a new stake in Danaher in the second quarter valued at $51,000. Finally, Western Pacific Wealth Management LP bought a new position in Danaher during the 1st quarter valued at $55,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.
Danaher Price Performance
Shares of NYSE:DHR opened at $247.76 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The firm’s 50 day moving average is $266.95 and its two-hundred day moving average is $260.51. The firm has a market capitalization of $178.95 billion, a P/E ratio of 47.28, a PEG ratio of 4.45 and a beta of 0.83. Danaher Co. has a 52 week low of $190.95 and a 52 week high of $281.70.
Danaher Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s payout ratio is currently 20.61%.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on DHR. KeyCorp upped their target price on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Bank of America upped their price objective on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Leerink Partners lifted their target price on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Stifel Nicolaus upped their price target on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research report on Wednesday, October 23rd. Finally, Raymond James decreased their price objective on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $287.16.
View Our Latest Analysis on DHR
Insider Activity at Danaher
In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 11.10% of the stock is currently owned by insiders.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
See Also
- Five stocks we like better than Danaher
- What is a Death Cross in Stocks?
- Battle of the Retailers: Who Comes Out on Top?
- 3 Small Caps With Big Return Potential
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- Are Penny Stocks a Good Fit for Your Portfolio?
- MarketBeat Week in Review – 10/28 – 11/1
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.